dm+d

Unassigned

New Medicines

Huntington's disease

Information

New molecular entity
Prilenia
Prilenia

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Dopamine D2 receptor antagonist/dopamine receptor agonist
The prevalence is estimated at between 1 in 10,000 and 1 in 20,000 [8].
Huntington's disease
Oral